Corient Capital Partners’s Idexx Laboratories IDXX Stock Holding History

Corient Capital Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.2M	Buy	3,420 +29	+0.9%	+$10.7K	0.09%	186
2022 Q2	$1.19M	Buy	3,391 +502	+17%	+$205K	0.09%	194
2022 Q1	$1.58M	Buy	2,889 +1,568	+119%	+$825K	0.1%	175
2021 Q4	$869K	Sell	1,321 -32	-2%	-$20.1K	0.06%	250
2021 Q3	$841K	Buy	1,353 +101	+8%	+$67.9K	0.06%	241
2021 Q2	$791K	Buy	1,252 +86	+7%	+$47.5K	0.06%	255
2021 Q1	$571K	Buy	1,166 +209	+22%	+$105K	0.05%	292
2020 Q4	$478K	Buy	957 +51	+6%	+$22.8K	0.05%	278
2020 Q3	$356K	Sell	906 -110	-11%	-$40.7K	0.04%	304
2020 Q2	$335K	Buy	1,016 +120	+13%	+$34.7K	0.04%	310
2020 Q1	$217K	Buy	+896	New	+$234K	0.03%	345
2019 Q4	–	Sell	-813	Closed	-$221K	–	477
2019 Q3	$221K	Buy	+813	New	+$226K	0.03%	387

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Corient Capital Partners's IDXX Position: Q3 2022 in Review

Corient Capital Partners increased its Idexx Laboratories (IDXX) stake by 0.86% in Q3 2022, buying an estimated $10.7K and bringing the position to 3,420 shares worth $1.2M. The position accounts for 0.09% of the portfolio, ranked #186.

Corient Capital Partners first reported a position in IDXX in Q3 2019 and has held it in 12 quarters since. The position peaked at $1.58M in Q1 2022. 924 funds tracked by Wall St. Rank hold IDXX as of Q3 2022.

Corient Capital Partners held 3,420 shares of Idexx Laboratories worth $1.2M as of Q3 2022.
Corient Capital Partners bought 29 Idexx Laboratories shares in Q3 2022, an estimated $10.7K.
Idexx Laboratories made up 0.09% of Corient Capital Partners's portfolio in Q3 2022, its #186 holding.
Corient Capital Partners first reported a position in Idexx Laboratories in Q3 2019 and has held it in 12 quarters since.
Corient Capital Partners's Idexx Laboratories position peaked at $1.58M in Q1 2022.
924 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.